Serotonin 

 448 Products   448 Products   1070 Diseases   113911 News 


«12...4546474849505152535455...11171118»
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Preclinical, Journal, Stroma:  Wnt16 Increases Bone-to-Implant Contact in an Osteopenic Rat Model by Increasing Proliferation and Regulating the Differentiation of Bone Marrow Stromal Cells. (Pubmed Central) -  May 9, 2024   
    We used an established rat model of cortical and trabecular femoral bone impairment following botox injections (2 injections of 8 units/leg each, starting and maintenance doses) to assess Wnt16 effects on whole bone morphology and implant osseointegration...They suggest a role for Wnt16 in modulating bone remodeling by reducing osteoclastic activity. Targeted strategies to temporally regulate Wnt16 after implant placement could be used to improve osseointegration by increasing the net pool of osteoprogenitor cells.
  • ||||||||||  Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir, Tagrisso (osimertinib) / AstraZeneca
    Journal:  A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma. (Pubmed Central) -  May 9, 2024   
    Targeted strategies to temporally regulate Wnt16 after implant placement could be used to improve osseointegration by increasing the net pool of osteoprogenitor cells. The measurement of osimertinib, AZ5104, and AZ7550 from hemaPEN microsampled DBS is a convenient and reliable approach for therapeutic drug monitoring that produces measurements consistent with plasma drug levels.
  • ||||||||||  chlorpromazine / Generic mfg., carbamazepine / Generic mfg., clozapine / Generic mfg.
    Journal, Adverse events:  Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database. (Pubmed Central) -  May 9, 2024   
    Apart from the expected association with clozapine, chlorpromazine and cyamemazine (sharing an aromatic heteropolycyclic molecular structure) emerged with a higher-than-expected reporting of DRESS. Better knowledge of the antipsychotic-related DRESS syndrome should increase clinicians' awareness leading to safer prescribing of antipsychotics.
  • ||||||||||  dexamethasone / Generic mfg., ondansetron / Generic mfg.
    Trial completion date, Trial primary completion date, Surgery:  PONV Prevention Via Percutaneous Nerve Electrical Stimulation on PC6 (clinicaltrials.gov) -  May 9, 2024   
    P2,  N=302, Recruiting, 
    Better knowledge of the antipsychotic-related DRESS syndrome should increase clinicians' awareness leading to safer prescribing of antipsychotics. Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024
  • ||||||||||  ondansetron / Generic mfg.
    Trial completion date, Trial primary completion date:  Noninvasive Markers of Functional Nausea in Children (clinicaltrials.gov) -  May 9, 2024   
    P=N/A,  N=130, Enrolling by invitation, 
    Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
  • ||||||||||  dextroamphetamine immediate release / Generic mfg.
    Journal:  Effective-connectivity of thalamocortical interactions following d-amphetamine, LSD, and MDMA administration. (Pubmed Central) -  May 8, 2024   
    Based on this proposal, each care setting can draw up a balanced scorecard adjusted to its priorities and care objectives, which will allow for comparison between centers. The results advance our knowledge about the action of psychedelics on the brain and refine current models aiming to explain the underlying neurobiological processes.
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Dexamethasone vs Ondansetron After Cesarean Delivery (clinicaltrials.gov) -  May 8, 2024   
    P4,  N=100, Completed, 
    The results advance our knowledge about the action of psychedelics on the brain and refine current models aiming to explain the underlying neurobiological processes. Not yet recruiting --> Completed | Trial completion date: Mar 2026 --> Apr 2024 | Trial primary completion date: Mar 2026 --> Apr 2024
  • ||||||||||  paroxetine / Generic mfg.
    Trial completion date, Trial primary completion date:  Effects of Paroxetine on Cardiovascular Function in Septic Patients (clinicaltrials.gov) -  May 8, 2024   
    P2,  N=92, Recruiting, 
    Not yet recruiting --> Completed | Trial completion date: Mar 2026 --> Apr 2024 | Trial primary completion date: Mar 2026 --> Apr 2024 Trial completion date: Feb 2024 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jul 2024
  • ||||||||||  psilocybin / Silo Pharma
    Trial completion, Trial completion date, Trial primary completion date:  PDP: Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease (clinicaltrials.gov) -  May 8, 2024   
    P2,  N=12, Completed, 
    Additional research is required to assess new-generation antidepressants for their propensity to cause DILI. Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: Apr 2024 --> Jun 2023
  • ||||||||||  fluoxetine / Generic mfg.
    Preclinical, Journal:  NSC689857, an inhibitor of Skp2, produces antidepressant-like effects in mice. (Pubmed Central) -  May 7, 2024   
    In addition, NSC689857 and fluoxetine coadministration produced additive antidepressant-like effects in non-stressed male mice...Administration of NSC689857 (5?mg/kg) also attenuated depression-like behaviors in male mice induced by chronic social defeat stress, suggesting therapeutic potential of NSC689857 in depression. Overall, these results suggest that NSC689857 is capable of exerting antidepressant-like effects in both non-stressed and chronically stressed mice.
  • ||||||||||  dasotraline (SEP-225289) / Sumitomo Pharma
    Clinical, Heterogeneity:  Estimating heterogeneity of treatment effect in psychiatric clinical trials. (Pubmed Central) -  May 7, 2024   
    Significant response heterogeneity was detected in other datasets as well, often despite no difference in variance between placebo and drug arms. The implications of eHTE as a clinical trial outcomes independent from central tendency of the group is considered and the important of the eHTE method and results for drug developers, providers, and patients is discussed.
  • ||||||||||  Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
    Review, Journal:  A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia. (Pubmed Central) -  May 7, 2024   
    In addition, improved adherence to treatment (adjunctive/monotherapy) with cariprazine in patients having inadequate response to an ongoing antipsychotic treatment has also been clinically established. This review presents the evidence-based safety and efficacy of cariprazine for treatment of predominant negative symptoms of schizophrenia.
  • ||||||||||  nelotanserin (RVT-102) / Roivant
    Preclinical, Journal:  Nelotanserin, a selective 5-HT2A receptor inverse agonist, attenuates aspects of nicotine withdrawal but not reward in mice. (Pubmed Central) -  May 6, 2024   
    However, nelotanserin had no effect on anxiety-like behavior and failed to reduce nicotine reward as measured in the conditioned place preference test. Our results suggest that inverse agonism of the 5-HT2A receptor may be a feasible novel mechanism for smoking cessation by reducing both physical withdrawal and thermal hyperalgesia associated with nicotine abstinence but may require complementary pharmacotherapies targeting affective and reward-associated decrements to improve cessation outcomes.
  • ||||||||||  Prolia (denosumab) / Amgen
    Denosumab-Induced Severe Hypocalcemia with Recurrent Side Effects (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_1652;    
    Denosumab-induced hypocalcemia is rare, but due to its severe effects on neuromuscular and cardiac function, patients should be counseled on the symptoms of hypocalcemia to ensure prompt medical evaluation. Ultimately, treatment for post-LTx osteoporosis should be individualized with consideration of specific medical history as well as routine monitoring of calcium levels when prescribed denosumab.
  • ||||||||||  aspirin / Generic mfg., escitalopram / Generic mfg., apixaban / Generic mfg.
    Journal:  Top 4 Research Studies of the month for Italian Primary Care Physicians: April 2024. (Pubmed Central) -  May 6, 2024   
    Trialists found that there was approximately 1 fewer ischemic stroke and 1 more major bleed for every 250 persons treated with apixaban instead of aspirin, but in people treated with apixaban major bleeding was also significantly more likely...3) In an intriguing but somewhat limited network meta-analysis, probiotics were equally or more effective than treatment with any antidepressant except escitalopram...Instead, they are associated with concerning risks of harm, most notably cerebral hemorrhage identified on imaging studies. The balance of risk versus benefit demonstrated thus far doesn't justify the use of these costly (over US$ 20,000 annually) drugs.
  • ||||||||||  Preclinical, Journal:  Testing of putative antiseizure medications in a preclinical Dravet syndrome zebrafish model. (Pubmed Central) -  May 6, 2024   
    Thus far, we have screened more than 3000 drug candidates in scn1lab zebrafish mutants, identifying valproate, stiripentol, and fenfluramine e.g. Food and Drug Administration-approved drugs, with clinical application in the Dravet syndrome population...Here, we curated a list of nine anti-seizure drug candidates recently identified by other groups using preclinical Dravet syndrome models: 1-Ethyl-2-benzimidazolinone, AA43279, chlorzoxazone, donepezil, lisuride, mifepristone, pargyline, soticlestat and vorinostat...Surprisingly, soticlestat induced frank electrographic seizure-like discharges in wild-type control zebrafish. Taken together, our results failed to replicate clear anti-seizure efficacy for these drug candidates highlighting a necessity for strict scientific standards in preclinical identification of anti-seizure medications.
  • ||||||||||  alhydrogel injectable (AD04) / ADvantage Therap, ondansetron ultra-low dose (AD04) / Adial
    Clinical, Clinical Trial,Phase II, Journal:  "Time Saved" Calculations to Improve Decision-Making in Progressive Disease Studies. (Pubmed Central) -  May 6, 2024   
    The relevance of 11 months saved is more universally understood than a mean difference of 3.8 points in the composite outcome. These results suggest that a combination of a composite approach and a time savings interpretation offers a powerful approach for detecting and interpreting disease modifying effects.
  • ||||||||||  centanafadine SR (EB-1020) / Otsuka
    Enrollment open, Trial completion date, Trial primary completion date:  A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD) (clinicaltrials.gov) -  May 6, 2024   
    P3,  N=570, Recruiting, 
    These results suggest that a combination of a composite approach and a time savings interpretation offers a powerful approach for detecting and interpreting disease modifying effects. Active, not recruiting --> Recruiting | Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2023 --> Oct 2025
  • ||||||||||  memantine / Generic mfg.
    Trial completion date, Trial primary completion date:  Memantine Augmentation of Targeted Cognitive Training in Schizophrenia (clinicaltrials.gov) -  May 6, 2024   
    P2/3,  N=69, Recruiting, 
    Active, not recruiting --> Recruiting | Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2023 --> Oct 2025 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
  • ||||||||||  Review, Journal:  Effects of antipsychotics on the gastrointestinal microbiota: A systematic review. (Pubmed Central) -  May 5, 2024   
    Twelve articles were considered eligible for the review, which investigated the effects of risperidone (5 studies), quetiapine (3), amilsupride (1), olanzapine (1), and unspecified atypical drugs (2)...In this way, the effects of APs on GM composition and diversity were inconclusive. Despite the uncertain interactions, a more comprehensive understanding on how microbiota is affected by APs may help to optimize treatment, potentially minimizing side effects and improving adherence to treatment.